Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Short term Debt (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Short term Debt for 4 consecutive years, with $339000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt changed N/A to $339000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $339000.0, a N/A change, with the full-year FY2021 number at $1.3 million, up 45.91% from a year prior.
  • Short term Debt was $339000.0 for Q3 2025 at Vivos Therapeutics, up from $157000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.3 million in Q2 2021 to a low of $157000.0 in Q2 2025.